SOFIVA Business Summary

SOFIVA Genomics Co., Ltd. (6615.TWO) operates a fee-for-service medical diagnostic model specializing in comprehensive genetic testing and clinical interpretation. The company’s revenue is primarily derived from six core business segments: reproductive medicine (PGT-A/M), prenatal and pre-pregnancy screening (NIPS), newborn genetic screening, precision oncology, rare disease diagnostics, and precision medication. As of 2026, SOFIVA has aggressively pivoted toward the early cancer screening market, leveraging circulating tumor DNA (ctDNA) technology integrated with its proprietary Herxin Health Management Centers to provide a closed-loop diagnostic ecosystem. In the competitive landscape of the Taipei Exchange, SOFIVA maintains a specialized clinical niche against broader biotech peers such as Bionet (1784.TW), Level Biotechnology (3118.TW), and CHC Healthcare Group (4164.TW), distinguishing itself through deep integration with maternal-fetal medical networks and high-throughput sequencing expertise. The leadership team is anchored by Founder and Chairwoman Dr. Yi-Ning Su, a prominent clinical professor at National Taiwan University (NTU) with an extensive pedigree in maternal-fetal medicine and medical genetics. Under her strategic direction, the company is managed by CEO and General Manager Dr. Chia-Cheng Hung, who oversees the technical execution of SOFIVA’s multi-channel expansion into the Asia-Pacific region, including Thailand and Japan. The board is notably supported by institutional representation from YIRAY Investment Co., Ltd., with key directors such as Chen Chun-Hui and Chen Ting-Yu providing corporate governance. This executive core combines academic clinical authority with commercial scaling experience, positioning the firm as a leading genomic laboratory in the regional precision medicine sector.